Gross Jane A 4
4 · Aptevo Therapeutics Inc. · Filed Jul 29, 2020
Insider Transaction Report
Form 4
Gross Jane A
See Remarks
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2020-07-27−2,072→ 0 totalExercise: $34.58Exp: 2021-03-10→ Common Stock (2,072 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-07-27−3,908→ 0 totalExercise: $41.58Exp: 2026-02-28→ Common Stock (3,908 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-07-27−2,407→ 0 totalExercise: $27.44Exp: 2027-02-24→ Common Stock (2,407 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-07-27−4,814→ 0 totalExercise: $43.82Exp: 2028-03-09→ Common Stock (4,814 underlying) - Award
Stock Option (right to buy)
2020-07-27+7,784→ 7,784 totalExercise: $8.56Exp: 2030-07-26→ Common Stock (7,784 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-07-27−2,779→ 0 totalExercise: $35.70Exp: 2022-03-09→ Common Stock (2,779 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-07-27−2,407→ 0 totalExercise: $30.10Exp: 2027-06-01→ Common Stock (2,407 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-07-27−4,814→ 0 totalExercise: $21.28Exp: 2029-02-28→ Common Stock (4,814 underlying) - Award
Stock Option (right to buy)
2020-07-27+2,140→ 2,140 totalExercise: $8.56Exp: 2030-07-26→ Common Stock (2,140 underlying)
Footnotes (11)
- [F1]Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020.
- [F10]These options vest in full on the one year anniversary of the date of grant.
- [F11]These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant.
- [F2]This stock option award vested on March 10, 2017. This award was originally part of a grant from Emergent BioSolutions Inc. ("Emergent") dated March 11, 2014, of which two-thirds were vested at the time of conversion to the issuer's equity pool.
- [F3]In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4.
- [F4]This stock option award vested on March 10, 2018. This award was originally part of a grant from Emergent dated March 11, 2015, of which two-thirds were vested at the time of conversion to the issuer's equity pool.
- [F5]This stock option award vested over three years, and the final one-third vested on March 1, 2019.
- [F6]This stock option award vested over three years, and the final one-third vested on February 24, 2020.
- [F7]This stock option award vested over three years, and the final one-third vested on June 1, 2020.
- [F8]This stock option award provides for vesting in three approximately equal annual installments beginning on March 9, 2019. Prior to July 27, 2020, all but 1,605 shares of the issuer's common stock underlying this stock option had vested.
- [F9]This stock option award provides for vesting in three approximately equal annual installments beginning on February 28, 2020. Prior to July 27, 2020, all but 3,210 shares of the issuer's common stock underlying this stock option had vested.